The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.
18 years of age or older.
Breast cancer
Lung cancer
Muscle invasive bladder cancer
Pregnant or breastfeeding.
Prior history and treatment for any cancer within the past year or has another active cancer, with the exception of participants who have undergone surgical removal of skin squamous cell or basal cell cancers.
Has initiated postoperative systemic treatment.
At time of enrollment, has undergone or plans to undergo any ctDNA testing to assess molecular residual disease, with the exception of comprehensive genomic profiling for therapeutic selection.
Participants 18 years of age or older diagnosed with malignant, invasive solid tumors prior to receiving treatment.
Cohort
Prospective
Not listed
Primary Outcome - Collection of Blood and Residual Tissue Specimens for Cancer Assay Development
To collect de-identified whole blood and residual tissue specimens for research use and the development of blood-based cancer monitoring and detection assays.
Secondary Outcome - Collection of Blood and Residual Tissue Specimens for Disease Assay Development
To collect de-identified whole blood and residual tissue specimens for research use and the development of blood-based disease assays.
Click on the lead sponsor to view all of their trials.
